

Innovations in the management of musculoskeletal pain with alpha-lipoic acid

Submission date 10/03/2016	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 15/03/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 21/05/2021	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Pain is a major problem affecting one-third of Canadians and costing \$850 billion/year in North America alone. Fibromyalgia (FM) is a common long-term condition, which causes widespread muscle and joint pain all over the body. The exact cause of FM is unknown, but it is thought that a variety of physical, mental and emotional factors are responsible. FM is also common in elderly patients emphasizing the urgent need to improve treatment as the population ages. Current pain-relieving medications (analgesics) used provide incomplete relief and disabling side effects such as tiredness and mental slowing – already prominent in people suffering from FM, and the elderly. Alpha-lipoic acid (ALA) is an antioxidant which has proven effective in the treatment of neuropathic pain (pain caused by nerve damage) with minimal side effects. ALA could potentially be an effective treatment for FM, as it does not make existing symptoms, such as tiredness and mental slowing, worse. The aim of this study is to test the effectiveness of ALA in treating pain in FM.

Who can participate?

Adults with fibromyalgia who have experienced at least moderate pain for at least three months.

What does the study involve?

Participants are randomly allocated to one of two groups who receive the two treatments in a different order. One treatment involves receiving the study medication (ALA) by mouth, three times a day for four weeks. The other treatment involves taking an identical looking placebo (dummy pill) by mouth, three times a day for four weeks. Each of the treatment periods will consist of three weeks of gradual dose increase, a week taking the maximal dose treatment (week four) and a 'washout' week when no study medication is taken at all (week five). Participants in both groups are interviewed by telephone every week in order to find out if the medication has had an effect on their pain intensity.

What are the possible benefits and risks of participating?

Participants may possibly benefit from pain reduction after taking the ALA. There is a small risk that participants may experience unwanted side effects from the ALA, including nausea and vomiting, headache and vertigo (spinning sensation when still).

Where is the study run from?
Providence Care, Kingston (Canada)

When is the study starting and how long is it expected to run for?
November 2015 to December 2018

Who is funding the study?
Physicians Services Incorporated Foundation (Canada)

Who is the main contact?
Dr Ian Gilron

Contact information

Type(s)
Scientific

Contact name
Dr Ian Gilron

Contact details
Kingston General Hospital
Victory 2 Pavillion
76 Stuart Street
Kingston
Canada
K7L2V7

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ANAE-287-15

Study information

Scientific Title
Double-blind, randomized, placebo-controlled trial of alpha-lipoic acid for fibromyalgia

Acronym
IMPALA

Study objectives
Alpha-lipoic acid is safe and superior to placebo in treating pain in fibromyalgia.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board, 03/12/2015, ref: ROMEO/TRAQ #6016602

Study design

Single-center prospective interventional double-blind randomized placebo-controlled crossover trial

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Fibromyalgia

Interventions

Participants are randomly allocated to one of two groups by the research pharmacist using a computer-generated randomization code.

Group 1: Participants are treated with alpha-lipoic acid 600 mg orally three times daily for four weeks, followed by one week washout period. The participants then take an identical looking placebo three times daily for four weeks.

Group 2: Participants are treated with a placebo orally three times daily for four weeks, followed by one week washout period. The participants then take alpha-lipoic acid 600 mg three times daily for four weeks.

Participants in both groups are contacted weekly by telephone to measure pain intensity.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Alpha-lipoic acid

Primary outcome measure

Pain intensity is measured using mean daily “average” pain intensity at maximal tolerated dose, of each period is determined by averaging the daily pain intensity, as measured using the 0-10 Numerical Rating Scale over the 7 days of week 4 of each treatment period (alpha-lipoic acid and placebo).

Secondary outcome measures

1. Adverse effects are measured using ratings of frequency and severity of treatment-emergent adverse effects weekly throughout the study
2. Fibromyalgia pain impact is measured using the fibromyalgia Impact Questionnaire at 4 and 9 weeks
3. Sleep quality is measured using the Medical Outcomes Study Sleep Scale at 4 and 9 weeks
4. Global treatment response is measured using the Patient Global Impression of Change at 4 and 9 weeks
5. Fibromyalgia pain impact is measured using the Brief Pain Inventory at 4 and 9 weeks
6. Mood is measured using the Beck Depression Inventory-2 at 4 and 9 weeks
7. Anxiety is measured using the Beck Anxiety Inventory at 4 and 9 weeks
8. Pain quality descriptors are measured using the short form McGill Pain Questionnaire at 4 and 9 weeks
9. Quality of life is measured using the SF-36 survey at 4 and 9 weeks
10. Quality of treatment blinding is measured using a blinding questionnaire at 4 and 9 weeks
11. Acetaminophen consumption is measured using a daily diary at 4 and 9 weeks

Overall study start date

01/11/2015

Completion date

30/12/2018

Eligibility

Key inclusion criteria

1. Aged 18 and older
2. Meeting the 2010 American College of Rheumatology diagnostic criteria for fibromyalgia
3. Experienced at least moderate daily pain (Numerical Rating Scale $\geq 4/10$) for at least 3 months prior to study entry
4. AST (aspartate aminotransferase)/ALT (alanine aminotransferase) no greater than 20% the upper limit of normal
5. Serum creatinine no greater than 50% the upper limit of normal
6. Necessary abilities, visual acuity and language skills for pain diary completion and telephone communication with study nurses

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

30

Total final enrolment

27

Key exclusion criteria

1. Any major organ system disease
2. Major poorly controlled psychiatric disorder
3. Severe depression or suicidal ideation
4. Active substance abuse disorder
5. Lactose intolerance
6. Hypersensitivity to ALA
7. Painful condition more than 50% as severe as their fibromyalgia pain
8. Unwillingness to use a highly effective form of contraception (women of childbearing potential)

Date of first enrolment

01/07/2016

Date of final enrolment

30/04/2018

Locations

Countries of recruitment

Canada

Study participating centre

Providence Care

St. Mary's of the Lake Hospital

340 Union Street

Kingston

Canada

K7L 5A2

Sponsor information

Organisation

Physicians Services Incorporated Foundation

Sponsor details

4773 Yonge Street, Suite 5G
North York
Canada
M2N 0G2

Sponsor type

Research organisation

ROR

<https://ror.org/0385yzn06>

Funder(s)**Funder type**

Research organisation

Funder Name

Physicians' Services Incorporated Foundation

Alternative Name(s)

PSI Foundation, PSI

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Canada

Results and Publications**Publication and dissemination plan**

1. Planned publication in an indexed, peer-reviewed, biomedical journal
2. Planed presentation at an international scientific meeting

Intention to publish date

28/02/2019

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	28/03/2017		Yes	No
Results article		01/02/2021	21/05/2021	Yes	No